GILUPI extends its patent portfolio
Second Chinese patent was granted in March 2017
The patent (ZL201180024406.8), short titled “biodetector” is valid until 15 March 2031. The newly granted Chinese patent extends GILUPIs patent portfolio protecting next device generations with enhanced sensitivity and greater convenience for patients.
“The extension of our intellectual property into the Chinese market is important for our strategic orientation. It further significantly broadens our patent portfolio, protecting our proprietary GILUPI technology on a global scale” said Dr. Jens Pfannkuche, CEO of GILUPI GmbH.
GILUPI´s patent portfolio consist of 11 patent families and further patent applications that are currently subject to examination procedures for a number of inventions. Hence, further granted patents will follow soon.